INSPIREMD 1/18 DL-0001 (II2) - Net Assets
Based on the latest financial reports, INSPIREMD 1/18 DL-0001 (II2) has net assets worth €55.20 Million EUR (≈ $64.54 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€69.40 Million ≈ $81.14 Million USD) and total liabilities (€14.20 Million ≈ $16.60 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check II2 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €55.20 Million |
| % of Total Assets | 79.54% |
| Annual Growth Rate | 13.27% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 66.24 |
INSPIREMD 1/18 DL-0001 - Net Assets Trend (2021–2025)
This chart illustrates how INSPIREMD 1/18 DL-0001's net assets have evolved over time, based on quarterly financial data. Also explore how large is INSPIREMD 1/18 DL-0001's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for INSPIREMD 1/18 DL-0001 (2021–2025)
The table below shows the annual net assets of INSPIREMD 1/18 DL-0001 from 2021 to 2025. For live valuation and market cap data, see market value of INSPIREMD 1/18 DL-0001.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €55.20 Million ≈ $64.54 Million |
+52.97% |
| 2024-12-31 | €36.09 Million ≈ $42.19 Million |
-8.65% |
| 2023-12-31 | €39.50 Million ≈ $46.18 Million |
+127.11% |
| 2022-12-31 | €17.39 Million ≈ $20.33 Million |
-48.13% |
| 2021-12-31 | €33.53 Million ≈ $39.20 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to INSPIREMD 1/18 DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11919800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €357.49 Million | 647.62% |
| Total Equity | €55.20 Million | 100.00% |
INSPIREMD 1/18 DL-0001 Competitors by Market Cap
The table below lists competitors of INSPIREMD 1/18 DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gielda Praw Majatkowych Vindexus S.A.
WAR:VIN
|
$43.59 Million |
|
Star Comgistic Capital Co Ltd
TW:4930
|
$43.60 Million |
|
Rocketboots Ltd
AU:ROC
|
$43.61 Million |
|
Frigoglass S.A.I.C.
AT:FRIGO
|
$43.62 Million |
|
Sportshero Ltd
AU:SHO
|
$43.58 Million |
|
CANTOURAGE GROUP SE O.N.
F:HIGH
|
$43.58 Million |
|
DiGiSPICE Technologies Limited
NSE:DIGISPICE
|
$43.57 Million |
|
Pakka Limited
NSE:PAKKA
|
$43.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INSPIREMD 1/18 DL-0001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 36,086,000 to 55,201,000, a change of 19,115,000 (53.0%).
- Net loss of 48,786,000 reduced equity.
- New share issuances of 38,714,000 increased equity.
- Other factors increased equity by 29,187,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-48.79 Million | -88.38% |
| Share Issuances | €38.71 Million | +70.13% |
| Other Changes | €29.19 Million | +52.87% |
| Total Change | €- | 52.97% |
Book Value vs Market Value Analysis
This analysis compares INSPIREMD 1/18 DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.60x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.20x to 0.60x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €4.04 | €0.80 | x |
| 2022-12-31 | €2.09 | €0.80 | x |
| 2023-12-31 | €1.81 | €0.80 | x |
| 2024-12-31 | €1.36 | €0.80 | x |
| 2025-12-31 | €1.32 | €0.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INSPIREMD 1/18 DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -88.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -543.33%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.26x
- Recent ROE (-88.38%) is below the historical average (-75.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -44.49% | -331.88% | 0.11x | 1.18x | €-18.27 Million |
| 2022 | -106.31% | -357.59% | 0.21x | 1.42x | €-20.23 Million |
| 2023 | -50.42% | -320.97% | 0.13x | 1.21x | €-23.87 Million |
| 2024 | -88.69% | -456.63% | 0.15x | 1.30x | €-35.61 Million |
| 2025 | -88.38% | -543.33% | 0.13x | 1.26x | €-54.31 Million |
Industry Comparison
This section compares INSPIREMD 1/18 DL-0001's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $38,810,717,203
- Average return on equity (ROE) among peers: -27.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INSPIREMD 1/18 DL-0001 (II2) | €55.20 Million | -44.49% | 0.26x | $43.58 Million |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $17.76 Billion | 5.42% | 0.47x | $146.15K |
| BIORETEC OY (0TN) | $9.74 Million | -47.38% | 0.18x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $349.05 Billion | 12.63% | 0.39x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $703.81 Million | 25.76% | 0.12x | $711.77 Million |
| HeraMED Limited (1I4) | $2.77 Million | -198.14% | 0.62x | $28.30 Million |
| Medtronic PLC (2M6) | $15.97 Billion | 19.39% | 0.91x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $2.04 Billion | -11.08% | 0.32x | $401.71 Million |
| AVITA Medical Inc (51KB) | $84.74 Million | -31.47% | 0.16x | $172.49 Million |
| BRAINCOOL AB (5YL) | $145.93 Million | -30.32% | 0.11x | $21.56 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.33 Billion | -20.20% | 0.10x | $107.57 Million |
About INSPIREMD 1/18 DL-0001
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard c… Read more